Quantum-Si (QSI) AI Stock Analysis

• Market Cap: $258.59M
• Dividend Yield: N/A
• Average Volume (3M): 4.65M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.71
• Revenue Growth: 40.20%
• EPS Growth: -4.07%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 195,552,170
• 10 Day Avg. Volume: 4,068,173
• 30 Day Avg. Volume: 4,647,141
• PEG Ratio: -0.87
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 126.43
• P/FCF Ratio: -4.19
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 63.43
• Enterprise Value/Gross Profit: 122.80
• Enterprise Value/Ebitda: -1.77
• 1Y Price Target: $2.67
• Price Target Upside: 122.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $1.00 ▼(-16.67% Downside)

The score is held back primarily by weak financial performance (ongoing losses, negative margins, and declining revenue) and a clearly bearish technical setup (price below key moving averages with negative MACD). Offsetting this, the latest earnings call showed meaningful product-development milestones, cost control, and a strong cash position, but valuation metrics are not supportive given losses and no dividend data.

Positive Factors

Cash runway / balance sheet strength

A cash runway into Q2 2028 provides durable funding to complete Proteus R&D and early commercialization without immediate dilution. This multi-year liquidity supports hiring, manufacturing scale-up, and go-to-market activities, reducing execution risk over the next 2–3 years.

Proteus development milestone

Demonstrated sequencing on the Proteus prototype materially lowers technical risk for the next-generation platform. Achieving this milestone enhances credibility with customers and partners, accelerates regulatory and commercialization timelines, and strengthens long-term product leadership in protein sequencing.

Recurring consumables and kit launches

New sequencing and library kits deepen the razor/razorblade revenue model by increasing consumable relevance per installed instrument. Improved kits that lower sample input and boost multiplexing enhance user value and adoption retention, supporting durable, higher-margin recurring revenue over time.

Negative Factors

Persistent losses and declining revenue

Sustained negative margins and shrinking revenue undermine the company’s ability to self-fund operations and commercial expansion. Continued losses increase dependence on external capital, which can dilute shareholders and constrain long-term investment in manufacturing, sales, and clinical validation.

Long sales cycle in target markets

A 9–12 month sales cycle reduces revenue visibility and slows installed-base growth critical for consumable repeat purchases. Extended purchasing timelines increase working capital needs and delay scalable commercial returns, challenging sustainable growth and slowing network effects from broader adoption.

Low current commercial traction

Very low recent instrument and overall revenue indicate early-stage commercial traction, meaning consumable repeatability and service revenue remain limited. Scaling to a self-sustaining commercial model will require meaningful instrument adoption, which is resource intensive and uncertain in the near term.

Quantum-Si Business Overview & Revenue Model

Company Description

Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.

How the Company Makes Money

Quantum-Si generates revenue through multiple streams including the sale of its protein sequencing systems and reagents, as well as software licenses for its analytical tools. The company targets academic and commercial research institutions, pharmaceutical companies, and biotechnology firms that require advanced proteomic analysis capabilities. Significant partnerships with academic institutions and research organizations help to enhance its product development and validate its technology, potentially leading to further revenue opportunities. Additionally, QSI may explore collaborations for joint research projects or co-development agreements that can contribute to its earnings.

Quantum-Si Financial Statement Overview

Summary

Mixed fundamentals: low leverage (debt-to-equity 0.05) and a strong equity base, but weak profitability (net margin -31.20%, EBIT margin -32.43%) and declining revenue growth (-6.89%). Cash flow remains negative despite some improvement in free cash flow growth (+9.18%).

Income Statement

Quantum-Si's income statement reveals significant challenges, with negative net profit margins and declining revenue growth. The TTM data shows a gross profit margin of 53.17%, indicating some efficiency in managing production costs. However, the company struggles with profitability, as evidenced by a net profit margin of -31.20% and an EBIT margin of -32.43%. The revenue growth rate is negative, at -6.89%, suggesting declining sales. Overall, the company faces profitability issues that need addressing.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.05, indicating conservative leverage. However, the return on equity is negative at -47.64%, reflecting the company's inability to generate profit from shareholders' equity. The equity ratio is strong, with stockholders' equity making up a significant portion of total assets. While the company maintains a stable financial structure, profitability remains a concern.

Cash Flow

The cash flow statement highlights a challenging cash position, with negative operating cash flow and free cash flow. Despite this, the free cash flow to net income ratio is positive at 1.04, indicating that the company is generating some cash relative to its net losses. The free cash flow growth rate is positive at 9.18%, showing some improvement. However, the operating cash flow to net income ratio is negative, suggesting operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.18M	3.06M	1.08M	0.00	0.00	0.00
Gross Profit	1.64M	1.60M	488.00K	0.00	0.00	0.00
EBITDA	-113.96M	-103.98M	-91.80M	-111.77M	-93.94M	-35.80M
Net Income	-116.85M	-101.01M	-95.96M	-132.44M	-94.99M	-36.61M
Balance Sheet
Total Assets	260.13M	247.87M	298.25M	391.49M	503.23M	40.59M
Cash, Cash Equivalents and Short-Term Investments	225.84M	209.60M	257.74M	351.31M	471.30M	36.91M
Total Debt	4.61M	12.95M	15.30M	17.45M	8.08M	1.75M
Total Liabilities	24.97M	32.45M	26.63M	32.78M	26.19M	4.50M
Stockholders Equity	235.16M	215.42M	271.62M	358.71M	477.03M	36.09M
Cash Flow
Free Cash Flow	-105.22M	-92.38M	-99.31M	-101.30M	-72.58M	-33.03M
Operating Cash Flow	-101.25M	-87.80M	-94.04M	-90.56M	-66.81M	-32.57M
Investing Cash Flow	-41.27M	-32.67M	143.43M	137.19M	-450.94M	-461.00K
Financing Cash Flow	131.16M	35.88M	149.00K	1.91M	516.63M	37.01M

Quantum-Si Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QSI, the sentiment is Negative. The current price of 1.2 is below the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.27, and below the 200-day MA of 1.51, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 42.66 is Neutral, neither overbought nor oversold. The STOCH value of 32.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QSI.

Quantum-Si Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ERAS	59 Neutral	$3.14B	-22.88	-32.00%	―	―	45.66%
DSGN	55 Neutral	$577.04M	-8.90	-29.83%	―	―	-40.26%
SEER	54 Neutral	$104.32M	-1.37	-25.74%	―	13.77%	-4.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QSI	50 Neutral	$258.59M	-1.77	-52.44%	―	40.20%	-4.07%
FHTX	49 Neutral	$343.87M	-4.86	―	―	-3.91%	37.89%
TNYA	47 Neutral	$142.89M	-1.00	-96.44%	―	―	46.68%

Quantum-Si Corporate Events

Quantum-Si Updates Investor Presentation Highlighting Proteomics Strategy

On December 29, 2025, Quantum-Si posted an updated corporate presentation for investors on its website, outlining its strategy to capitalize on what it sees as a more than $75 billion and rapidly growing proteomics market. The materials highlight the company’s differentiated single-molecule protein sequencing technology, the growing user base and published data for its first-to-market Platinum Pro system, and plans to use Platinum Pro to build commercial infrastructure ahead of the planned Proteus platform launch, which is designed to deliver automated, high-value proteoform and post-translational modification analysis more broadly across laboratories. The presentation underscores Quantum-Si’s existing global distribution network, partnerships across commercialization, product development and manufacturing, a cash runway extending into the second quarter of 2028, and its view that scalable, affordable protein sequencing will be critical to meeting rising demand for complex, high-resolution proteomics across research and emerging clinical applications.

The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.

Quantum-Si Unveils Proteus Advancements at Investor Day

On November 19, 2025, Quantum-Si held its Investor & Analyst Day, presenting significant advancements in its Proteus program. The company highlighted the Proteus platform’s capabilities in deep protein analysis, automation, and affordability, which are expected to enhance proteomics research accessibility and efficiency. The Proteus platform, set for launch by the end of 2026, promises superior sequencing output and quality compared to existing technologies, positioning Quantum-Si as a leader in the proteomics field.

The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.